Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning

Journal of Otolaryngology - Head & Neck Surgery - Tập 52 Số 1 - 2023
Tsung-Ming Chen1, Wan-Ming Chen2, Mingchih Chen2, Ben‐Chang Shia2, Szu‐Yuan Wu3,4,2
1Department of Otolaryngology-Head and Neck Surgery, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan
2Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan
3Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan
4Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, No. 83, Nanchang St., 265, Luodong Township, Yilan County, Taiwan

Tóm tắt

Purpose No large-scale prospective randomized study with a long-term follow-up period has evaluated the survival outcomes of preconcurrent chemoradiotherapy (CCRT) 18-fluorodeoxyglucose positron emission tomography–computed tomography (18FDG PET–CT) in patients with non–human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). Patients and Methods We included patients with stage I–IVA p16-negative OPSCC receiving definitive CCRT and categorized them into two groups according to pre-CCRT 18FDG PET–CT and compared their outcomes: the case group consisted of patients who underwent pre-CCRT 18FDG PET–CT, whereas the comparison group consisted of patients who did not receive pre-CCRT 18FDG PET–CT. Results The final cohort consisted of 3942 patients (1663 and 2279 in the case and comparison groups, respectively). According to multivariable Cox regression analysis, pre-CCRT 18FDG PET–CT was not a significant prognostic factor for overall survival in patients with stages I–II of p16-negative OPSCC receiving standard CCRT. The adjusted hazard ratio (95% confidence interval) of all-cause death for the patients with advanced stages (III–IVA) of p16-negative OPSCC receiving pre-CCRT 18FDG PET–CT was 0.75 (0.87–0.94, P = 0.0236). Conclusions Routine use of pre-CCRT 18FDG PET–CT is not necessary for each patient with p16-negative OPSCC. Pre-CCRT 18FDG PET–CT is associated with improved survival in patients with stage III–IVA p16-negative OSCC, but might be not in those with stage I–II p16-negative OPSCC. Condensed abstract No large-scale prospective randomized study with a long-term follow-up period has evaluated the survival outcomes of preconcurrent chemoradiotherapy (CCRT) 18-fluorodeoxyglucose positron emission tomography–computed tomography (18FDG PET–CT) in patients with p16-negative oropharyngeal squamous cell carcinoma (OPSCC). Our study is the first, largest, homogenous modality study on PET–CT including a long-term follow-up cohort to examine the survival outcomes of pre-CCRT 18FDG PET–CT or non-pre-CCRT PET–CT for patients with p16-negative OPSCC receiving standard CCRT stratified by different clinical stages. Routine use of pre-CCRT 18FDG PET–CT is not necessary for each patient with p16-negative OPSCC. Pre-CCRT 18FDG PET–CT is associated with improved survival in patients with stage III–IVA p16-negative OPSCC, but might be not in those with stage I–II p16-negative OPSCC.

Từ khóa


Tài liệu tham khảo

10.3322/canjclin.55.2.74

Health Promotion Administration MoHaW: Taiwan Cancer Registry Annual Report. 2018.

10.1093/jnci/djv344

10.1002/cncr.33221

10.1038/s41572-020-00224-3

10.1016/j.jobcr.2017.08.003

10.1093/annonc/mdm270

10.1016/j.oraloncology.2005.07.009

10.1097/00005537-200305000-00021

10.1097/MLG.0b013e31805d017b

10.1002/hed.10006

10.1016/S0002-9610(96)00313-3

10.1200/JCO.2009.24.6298

NCCN Clinical practice guidelines in oncology: Head and Neck Cancer

10.1002/cncr.10567

10.1016/j.radonc.2009.04.014

10.1200/JCO.19.00463

10.1002/hed.21566

10.1016/j.suronc.2013.06.002

10.1016/j.ijrobp.2004.03.040

10.1056/NEJMoa1514493

10.1001/archoto.2009.152

10.1200/JCO.18.00684

10.1001/jamanetworkopen.2021.20156

10.1001/jamanetworkopen.2021.1785

10.1016/j.radonc.2020.08.016

10.1038/srep24332

10.1016/0895-4356(94)90129-5

10.1002/ssu.10019

10.1016/j.semradonc.2018.02.001

10.1016/j.radonc.2010.04.025

10.1016/j.ijrobp.2007.02.017

10.3389/fonc.2012.00189

10.1097/RLU.0000000000003739

10.3389/fonc.2020.566318

10.1016/0964-1955(94)90013-2

10.3390/cancers11020227

10.3389/fonc.2017.00129

10.1016/j.ijrobp.2016.11.044

10.1001/jamaoto.2019.1187

10.1002/cncr.30843

10.1002/lary.24704

Verma V, 2018, JAMA Otolaryngol Head Neck Surg, 144, 86

10.1002/hed.2880120302

10.1097/01.mlg.0000217543.40027.1d

10.1200/JCO.18.01921

10.1016/j.ctrv.2017.07.004

10.2214/AJR.13.12420

10.1186/1471-2407-12-98

10.1186/s13014-016-0739-y

10.1097/RLU.0000000000003789

10.1016/S0140-6736(19)30956-0

10.2188/jea.JE20140076

10.1002/pds.2087

Lin CC, 2005, J Formos Med Assoc, 104, 157

Thông tin
Thông tin xuất bản

Journal of Otolaryngology - Head & Neck Surgery

Tập 52 Số 1

Thông tin tác giả